Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net (loss) income	$ (1,393,356)	$ 8,176,871
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Change in reserve for supplier advances for purchases	20,900	26,410
Bad debt expense - related party	105,465	71,796
Gain on sale of equipment	(39,667)
(Gain) loss on settlement of debt	(8,150)	153,172
Depreciation	18,188	22,682
Stock-based compensation		20,500
Stock-based loan modification cost		10,575
Amortization of convertible notes receivable discount	(3,031)	(16,215)
Change in fair value of convertible notes and derivatives	187,829	(11,023,290)
Amortization of loan discount	142,639	537,425
Amortization of operating lease right-of-use assets	77,429	93,810
Changes in operating assets and liabilities:
Decrease (increase) in accounts receivable	(769)	24,334
Increase in inventory	(40,278)	25,733
Increase in other receivable	(47,363)	(15,000)
Decrease (increase) in prepaid expenses and other current assets	11,752	(23,410)
Increase (decrease) in accounts payable	35,590	54,996
Increase in accrued expenses	222,470	826,557
Increase in accrued payroll due to officers	160,000	160,000
Increase in deferred revenue - related party	51,816	181,515
Increase (decrease) in accrued interest to related parties	23,337	6,780
Decrease in operating lease obligations	(74,837)	(77,673)
Net cash used in operating activities	(550,036)	(762,432)
Cash flows from investing activities:
Sale of Stemsation stock	33,516
Convertible notes receivable advances	(12,310)	(16,451)
Convertible notes receivable repayments	12,500	101,750
Proceeds from sale of equipment	83,649
Acquisition of equipment		(57,993)
Net cash provided by investing activities:	117,355	27,306
Cash flows from financing activities:
Loans from officer	599,500	103,385
Repayment of officer loans	(162,100)	(267,500)
Proceeds from convertible notes	127,250	760,000
Repayment of convertible notes	(46,716)	(114,920)
Advances from other notes payable	182,200	464,852
Repayments of other notes payable	(267,453)	(301,601)
Net cash provided by financing activities	432,681	644,216
Net change in cash		(90,910)
Cash - beginning of period		90,910
Cash - end of period
Supplemental Cash Flow Information:
Cash paid for interest	87,424	84,460
Cash paid for income taxes
Non Cash Financing and Investing:
Common stock issued in settlement of notes		276,752
Common stock issued for debt modification and penalty		10,575
Common stock issued for conversion of debt	2,500	36,000
Warrants issued with Debt--Debt discount		100,000
Increase in right-of-use assets and operating lease liabilities due to lease renewal		251,951
Stemsation shares awarded but not yet issued in settlement of convertible notes receivable	160,084
Stemsation shares received in settlement of convertible notes receivable	103,916
Reclassification of other receivable to convertible notes receivable	$ 42,363	$ 21,000